Publikationen von Vatter, Hartmut

Weller, Johannes , Schäfer, Niklas, Schaub, Christina, Potthoff, Anna-Laura, Steinbach, Joachim P., Schlegel, Uwe, Sabel, Michael , Hau, Peter , Seidel, Clemens, Krex, Dietmar, Goldbrunner, Roland, Pietsch, Torsten, Tzaridis, Theophilos, Zeyen, Thomas, Borger, Valeri, Güresir, Erdem, Vatter, Hartmut, Herrlinger, Ulrich und Schneider, Matthias (2022) Prognostic impact of obesity in newly-diagnosed glioblastoma: a secondary analysis of CeTeG/NOA-09 and GLARIUS. Journal of Neuro-Oncology 159 (1), S. 95-101.

Zeyen, Thomas, Potthoff, Anna-Laura, Nemeth, Robert, Heiland, Dieter H., Burger, Michael C., Steinbach, Joachim P., Hau, Peter, Tabatabai, Ghazaleh, Glas, Martin, Schlegel, Uwe, Grauer, Oliver, Krex, Dietmar, Schnell, Oliver, Goldbrunner, Roland, Sabel, Michael , Thon, Niklas, Delev, Daniel, Clusmann, Hans, Seidel, Clemens, Güresir, Erdem, Schmid, Matthias , Schuss, Patrick , Giordano, Frank A., Radbruch, Alexander, Becker, Albert, Weller, Johannes, Schaub, Christina, Vatter, Hartmut, Schilling, Judith, Winkler, Frank , Herrlinger, Ulrich und Schneider, Matthias (2022) Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy—the MecMeth/NOA-24 trial. Trials 23 (1). Volltext nicht vorhanden.

Güresir, Erdem, Lampmann, Tim, Brandecker, Simon, Czabanka, Marcus, Fimmers, Rolf, Gempt, Jens, Haas, Patrick, Haj, Amer, Jabbarli, Ramazan, Kalasauskas, Darius, König, Ralph, Mielke, Dorothee, Németh, Robert, Oppong, Marvin Darkwah , Pala, Andrej, Prinz, Vincent, Ringel, Florian, Roder, Constantin, Rohde, Veit, Schebesch, Karl-Michael, Wagner, Arthur , Coch, Christoph und Vatter, Hartmut (2022) PrImary decompressive Craniectomy in AneurySmal Subarachnoid hemOrrhage (PICASSO) trial: study protocol for a randomized controlled trial. Trials 23 (1). Volltext nicht vorhanden.

Tzaridis, Theophilos , Schäfer, Niklas, Weller, Johannes, Steinbach, Joachim‐Peter, Schlegel, Uwe, Seidel, Sabine, Sabel, Michael, Hau, Peter, Seidel, Clemens, Krex, Dietmar, Goldbrunner, Roland, Tonn, Jörg‐Christian, Grauer, Oliver, Kebir, Sied, Schneider, Matthias, Schaub, Christina, Vatter, Hartmut, Coch, Christoph, Glas, Martin, Fimmers, Rolf, Pietsch, Torsten, Reifenberger, Guido, Herrlinger, Ulrich und Felsberg, Jörg (2021) MGMT promoter methylation analysis for allocating combined CCNU / TMZ chemotherapy: Lessons learned from the CeTeG / NOA ‐09 trial. International Journal of Cancer 148 (7), S. 1695-1707. Volltext nicht vorhanden.

Schäfer, Niklas, Bumes, Elisabeth, Eberle, Fabian , Fox, Viola, Gessler, Florian, Giordano, Frank A., Konczalla, Juergen, Onken, Julia, Ottenhausen, Malte, Scherer, Moritz, Schneider, Matthias, Vatter, Hartmut, Herrlinger, Ulrich und Schuss, Patrick (2021) Implementation, relevance, and virtual adaptation of neuro-oncological tumor boards during the COVID-19 pandemic: a nationwide provider survey. Journal of Neuro-Oncology 153 (3), S. 479-485. Volltext nicht vorhanden.

Kebir, Sied, Schaub, Christina, Junold, Nina, Hattingen, Elke , Schäfer, Niklas, Steinbach, Joachim P., Weyerbrock, Astrid, Hau, Peter, Goldbrunner, Roland, Galldiks, Norbert , Weller, Johannes , Mack, Frederic, Tzaridis, Theophilos, Bähr, Oliver, Seidel, Clemens, Schlegel, Uwe, Schmidt-Graf, Friederike, Rohde, Veit, Borchers, Christian, Tabatabai, Ghazaleh , Hänel, Mathias, Sabel, Michael, Gerlach, Rüdiger, Krex, Dietmar, Belka, Claus, Vatter, Hartmut, Proescholdt, Martin, Glas, Martin und Herrlinger, Ulrich (2019) Baseline T1 hyperintense and diffusion-restricted lesions are not linked to prolonged survival in bevacizumab-treated glioblastoma patients of the GLARIUS trial. Journal of Neuro-Oncology 144 (3), S. 501-509. Volltext nicht vorhanden.

Herrlinger, Ulrich, Tzaridis, Theophilos, Mack, Frederic, Steinbach, Joachim Peter, Schlegel, Uwe, Sabel, Michael, Hau, Peter , Kortmann, Rolf-Dieter, Krex, Dietmar, Grauer, Oliver, Goldbrunner, Roland, Schnell, Oliver, Bähr, Oliver, Uhl, Martin, Seidel, Clemens, Tabatabai, Ghazaleh , Kowalski, Thomas, Ringel, Florian, Schmidt-Graf, Friederike, Suchorska, Bogdana, Brehmer, Stefanie, Weyerbrock, Astrid, Renovanz, Miriam, Bullinger, Lars, Galldiks, Norbert , Vajkoczy, Peter, Misch, Martin, Vatter, Hartmut, Stuplich, Moritz, Schäfer, Niklas, Kebir, Sied, Weller, Johannes , Schaub, Christina, Stummer, Walter, Tonn, Jörg-Christian, Simon, Matthias, Keil, Vera C., Nelles, Michael, Urbach, Horst, Coenen, Martin, Wick, Wolfgang , Weller, Michael , Fimmers, Rolf, Schmid, Matthias , Hattingen, Elke , Pietsch, Torsten, Coch, Christoph und Glas, Martin (2019) Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial. The Lancet 393 (10172), S. 678-688. Volltext nicht vorhanden.

Schaub, Christina, Kebir, Sied, Junold, Nina, Hattingen, Elke , Schäfer, Niklas, Steinbach, Joachim P., Weyerbrock, Astrid, Hau, Peter , Goldbrunner, Roland, Niessen, Michael, Mack, Frederic, Stuplich, Moritz, Tzaridis, Theophilos, Bähr, Oliver, Kortmann, Rolf-Dieter, Schlegel, Uwe, Schmidt-Graf, Friederike, Rohde, Veit, Braun, Christian, Hänel, Mathias, Sabel, Michael, Gerlach, Rüdiger, Krex, Dietmar, Belka, Claus, Vatter, Hartmut, Proescholdt, Martin, Herrlinger, Ulrich und Glas, Martin (2018) Tumor growth patterns of MGMT-non-methylated glioblastoma in the randomized GLARIUS trial. Journal of Cancer Research and Clinical Oncology 144 (8), S. 1581-1589. Volltext nicht vorhanden.